SCHEMBL941683

SCHEMBL941683

O=C(Cn1ccnc1[N+](=O)[O-])NCc1cn(CCO)nn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.61
▸ CYP2C19 P33261 2/20 0.61
▸ THRB P10828 1/20 0.61
▸ CYP3A4 P08684 2/20 0.57
▸ CYP2D6 P10635 1/20 0.57
▸ OPRK1 P41145 1/20 0.57
▸ CA12 O43570 5/20 0.53
▸ CA1 P00915 5/20 0.53
▸ CA2 P00918 5/20 0.53
▸ CA9 Q16790 5/20 0.53
▸ GUSB P08236 1/20 0.40
▸ APP P05067 2/20 0.39
▸ GLS O94925 2/20 0.38
▸ MAPK1 P28482 1/20 0.36
▸ KMT2A Q03164 2/20 0.35
▸ FNTA P49354 2/20 0.34
▸ FNTB P49356 2/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL942527 0.91 CYP3A4 (0.56) LMNACYP2C19THRBCYP3A4CYP2D6
SCHEMBL13104167 0.91 CYP3A4 (0.56) LMNACYP2C19THRBCYP3A4CYP2D6
SCHEMBL14043067 0.84 MAPK1 (0.42) LMNACYP2C19THRBCYP3A4CYP2D6
SCHEMBL941529 0.82 LMNA (0.46) LMNACYP2C19THRBCYP3A4CYP2D6
SCHEMBL943760 0.81 CA12 (0.51) LMNACYP2C19THRBCYP3A4CYP2D6
Etanidazole SCHEMBL8171462 0.77 LMNA (1.00) LMNACYP2C19THRBCYP3A4CYP2D6
Etanidazole SCHEMBL4414 0.77 LMNA (1.00) LMNACYP2C19THRBCYP3A4CYP2D6
SCHEMBL15024639 0.77 LMNA (0.80) LMNACYP2C19THRBCYP3A4CYP2D6
Etanidazole SCHEMBL9473771 0.76 LMNA (0.97) LMNACYP2C19THRBCYP3A4CYP2D6
Benznidazole SCHEMBL45081 0.73 CYP3A4 (1.00) LMNACYP2C19THRBCYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2132200-B1 NITRO-IMIDAZOLE HYPOXIA IMAGING AGENTS THRESHOLD PHARMACEUTICALS INC (US) 2016-03-23 — — EP disclosed
EP-2132200-B1 NITRO-IMIDAZOLE HYPOXIA IMAGING AGENTS THRESHOLD PHARMACEUTICALS INC (US) 2016-03-23 — — EP disclosed
CN-101652360-B Nitroimidazol hypoxic contrast agents SIEMENS MEDICAL SOLUTIONS US 2014-06-25 — — CN disclosed
US-7977361-B2 Nitro-imidazole hypoxia imaging agent SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-12 — — US disclosed
US-7977361-B2 Nitro-imidazole hypoxia imaging agent SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-12 — — US disclosed
US-20110002850-A1 Nitro-Imidazole Hypoxia Imaging Agent SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-01-06 — — US disclosed
US-20110002850-A1 Nitro-Imidazole Hypoxia Imaging Agent SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-01-06 — — US disclosed
US-7807394-B2 Nitro-imidazole hypoxia imaging agents SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-10-05 — — US disclosed
US-7807394-B2 Nitro-imidazole hypoxia imaging agents SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-10-05 — — US disclosed
US-7807394-B2 Nitro-imidazole hypoxia imaging agents SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-10-05 — — US disclosed
CN-101652360-A Nitroimidazol hypoxic contrast agents SIEMENS MEDICAL SOLUTIONS US 2010-02-17 — — CN disclosed
EP-2132200-A2 NITRO-IMIDAZOLE HYPOXIA IMAGING AGENTS Siemens Medical Solutions USA, Inc. (US) 2009-12-16 — — EP disclosed
US-20090010846-A1 Nitro-Imidazole Hypoxia Imaging Agents SIEMENS MEDICAL SOLUTIONS USA, INC. 2009-01-08 — — US disclosed
US-20090010846-A1 Nitro-Imidazole Hypoxia Imaging Agents SIEMENS MEDICAL SOLUTIONS USA, INC. 2009-01-08 — — US disclosed
US-20090010846-A1 Nitro-Imidazole Hypoxia Imaging Agents SIEMENS MEDICAL SOLUTIONS USA, INC. 2009-01-08 — — US disclosed
WO-2008124651-A2 NITRO-IMIDAZOLE HYPOXIA IMAGING AGENTS SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2008-10-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090010846-A1 Nitro-Imidazole Hypoxia Imaging Agents HIF1AN, HIF1A, HYOU1 LMNA 3765/4885CYP2C19 277/4885THRB 2300/4885
US-20110002850-A1 Nitro-Imidazole Hypoxia Imaging Agent HIF1AN, HIF1A, HYOU1 LMNA 3725/4885CYP2C19 276/4885THRB 2243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback